Skip to main content
SpringerLink
Log in

Bleeding and Thrombosis in Hematologic Neoplasia

  • Chapter
  • First Online:
Neoplastic Diseases of the Blood

Abstract

Excessive bleeding or thrombosis complicates the treatment of many patients with hematologic malignancies. The pathogenesis and therapy of some of these disorders, such as thrombocytopenia due to invasion of the marrow by tumor cells or chemotherapy, is usually straightforward. However, other hemostatic defects are more complex. For example:

  1. 1.

    Malignant cells can produce and release thromboplastic or fibrinolytic substances that cause disseminated intravascular coagulation (DIC) or primary fibrinolysis (for example, acute promyelocytic leukemia) (APL).

  2. 2.

    The pathologic process can provoke the megakaryocyte to produce dysfunctional platelets with bleeding or thrombosis (chronic myeloproliferative disorders).

  3. 3.

    Abnormal lymphocytes or plasma cells sometimes produce aberrant proteins that interfere with normal hemostasis (multiple myeloma, amyloid).

  4. 4.

    Certain antitumor or antimicrobial agents used in the treatment of malignancy or its complications can cause thrombosis or bleeding (l-asparaginase or some β-lactam antibiotics).

This chapter focuses on bleeding and thrombotic disorders that are associated with hematologic neoplasia. Thrombocytopenic bleeding and of platelet transfusion therapy is covered elsewhere in this volume.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol. 2007;86(2):137–42.

    Article  PubMed  Google Scholar 

  2. Goodnight SH Jr. Bleeding and intravascular clotting in malignancy: a review. Ann N Y Acad Sci. 1974;230:271–88.

    Article  PubMed  Google Scholar 

  3. Baker WG, Bang NU, Nachman RL, Raafat F, Horowitz HI. Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin. With autopsy findings of widespread intravascular clotting. Ann Intern Med. 1964;61:116–23.

    Article  CAS  PubMed  Google Scholar 

  4. Leavey RA, Benham Kahn S, Brodsky I. Disseminated intravascular coagulation—a complication of chemotherapy in acute myelomonocytic leukemia. Cancer. 1970;26(1):142–5.

    Article  CAS  PubMed  Google Scholar 

  5. Shaw MT. The distinctive features of acute monocytic leukemia. Am J Hematol. 1978;4(1):97–103.

    Article  CAS  PubMed  Google Scholar 

  6. Straus DJ, Mertelsmann R, Koziner B, McKenzie S, de Harven E, Arlin ZA, et al. The acute monocytic leukemias: multidisciplinary studies in 45 patients. Medicine. 1980;59(6):409–25.

    Article  CAS  PubMed  Google Scholar 

  7. Tobelem G, Jacquillat C, Chastang C, Auclerc M, Lechevallier T, Weil M, et al. Acute monoblastic leukemia: a clinical and biologic study of 74 cases. Blood. 1980;55(1):71–6.

    CAS  PubMed  Google Scholar 

  8. Speiser W, Pabinger-Fasching I, Kyrle PA, Kapiotis S, Kottas-Heldenberg A, Bettelheim P, et al. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut. 1990;61(5):298–302.

    Article  CAS  PubMed  Google Scholar 

  9. French AJ, Lilleyman JS. Bleeding tendency of T-cell lymphoblastic leukaemia. Lancet. 1979;2(8140):469–70.

    Article  CAS  PubMed  Google Scholar 

  10. Gingrich RD, Burns CP. Disseminated coagulopathy in chronic myelomonocytic leukemia. Cancer. 1979;44(6):2249–53.

    Article  CAS  PubMed  Google Scholar 

  11. Hirsh J, Buchanan JG, De Gruchy GC, Baikie AG. Hypofibrinogenaemia without increased fibrinolysis in leukaemia. Lancet. 1967;1(7487):418–20.

    Article  CAS  PubMed  Google Scholar 

  12. Champion LAA, Luddy RE, Schwartz AD. Disseminated intravascular coagulation in childhood acute lymphocytic leukemia with poor prognostic features. Cancer. 1978;41(4):1642–6.

    Article  CAS  PubMed  Google Scholar 

  13. Edson JR, Krivit W, White JG, Sharp HL. Intravascular coagulation in acute stem cell leukemia successfully treated with heparin. J Pediatr. 1967;71(3):342–50.

    Article  CAS  PubMed  Google Scholar 

  14. Tornebohm E, Egberg N, Sablica H, Wallin R, Lockner D, Paul C. Elastase activity in leukaemic cells and plasma in patients with acute leukaemia. Eur J Haematol. 1992;49(2):98–104.

    Article  CAS  PubMed  Google Scholar 

  15. Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79(5):1305–10.

    CAS  PubMed  Google Scholar 

  16. Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, et al. Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol. 2015;4:22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, et al. Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol. 2015;4(1):1–15.

    Article  CAS  Google Scholar 

  18. Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol. 2014;100(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  19. Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol. 2001;115(2):382–91.

    Article  CAS  PubMed  Google Scholar 

  20. Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35(7):879–84.

    Article  CAS  PubMed  Google Scholar 

  21. Jourdan E, Dombret H, Glaisner S, Miclea JM, Castaigne S, Degos L. Unexpected high incidence of intracranial subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component. Br J Haematol. 1995;89(3):527–30.

    Article  CAS  PubMed  Google Scholar 

  22. Cuttner J, Conjalka MS, Reilly M, Goldberg J, Reisman A, Meyer RJ, et al. Association of monocytic leukemia in patients with extreme leukocytosis. Am J Med. 1980;69(4):555–8.

    Article  CAS  PubMed  Google Scholar 

  23. Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res. 2007;120(Suppl 2):S99–106.

    Article  PubMed  Google Scholar 

  24. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–8.

    Article  CAS  PubMed  Google Scholar 

  25. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–402.

    Article  PubMed  CAS  Google Scholar 

  26. Di Bona E, Avvisati G, Castaman G, Luce Vegna M, De Sanctis V, Rodeghiero F, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol. 2000;108(4):689–95.

    Article  PubMed  Google Scholar 

  27. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009;113(17):3911–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Myers T, Rickles F, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood. 1981;57(3):518–25.

    CAS  PubMed  Google Scholar 

  29. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, et al. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol. 2010;85(5):325–30.

    CAS  PubMed  Google Scholar 

  30. Reddy VB, Kowal-Vern A, Hoppensteadt DA, Kumar A, Walenga JM, Fareed J, et al. Global and molecular hemostatic markers in acute myeloid leukemia. Am J Clin Pathol. 1990;94(4):397–403.

    Article  CAS  PubMed  Google Scholar 

  31. Chojnowski K, Wawrzyniak E, Trelinski J, Niewiarowska J, Cierniewski C. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma. 1999;36(1–2):77–84.

    Article  CAS  PubMed  Google Scholar 

  32. Hasegawa DK, Bennett AJ, Coccia PF, Ramsay NK, Nesbit ME, Krivit W, et al. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood. 1980;56(4):585–95.

    CAS  PubMed  Google Scholar 

  33. Rodeghiero F, Barbui T, Battista R, Chisesi T, Rigoni G, Dini E. Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukaemia. Thromb Haemost. 1980;43(1):6–9.

    CAS  PubMed  Google Scholar 

  34. Wilson E, Jacobs P, Dowdle E. The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood. 1983;61(3):568–74.

    CAS  PubMed  Google Scholar 

  35. Cozzolino F, Torcia M, Miliani A, Carossino AM, Giordani R, Cinotti S, et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med. 1988;84(2):240–50.

    Article  CAS  PubMed  Google Scholar 

  36. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982;60(2):284–7.

    CAS  PubMed  Google Scholar 

  37. Rocha E, Paramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management. Haematologica. 1998;83(11):1024–37.

    CAS  PubMed  Google Scholar 

  38. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36(1):41–9.

    Article  CAS  PubMed  Google Scholar 

  39. Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002.

    Article  CAS  PubMed  Google Scholar 

  40. de Jonge E, Levi M, Stoutenbeek CP, van Deventer SJ. Current drug treatment strategies for disseminated intravascular coagulation. Drugs. 1998;55(6):767–77.

    Article  PubMed  Google Scholar 

  41. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol. 2009;22(1):153–63.

    Article  CAS  PubMed  Google Scholar 

  42. Cowan DH, Graham RC Jr, Baunach D. The platelet defect in leukemia. Platelet ultrastructure, adenine nucleotide metabolism, and the release reaction. J Clin Invest. 1975;56(1):188–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Maldonado JE, Pierre RV. The platelets in preleukemia and myelomonocytic leukemia. Ultrastructural cytochemistry and cytogenetics. Mayo Clin Proc. 1975;50(10):573–87.

    CAS  PubMed  Google Scholar 

  44. Leinoe EB, Hoffmann MH, Kjaersgaard E, Nielsen JD, Bergmann OJ, Klausen TW, et al. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol. 2005;128(4):526–32.

    Article  PubMed  Google Scholar 

  45. Van der Weyden MB, Clancy RL, Howard MA, Firkin BG. Qualitative platelet defects with reduced life-span in acute leukaemia. Aust NZ J Med. 1972;2(4):339–45.

    Article  Google Scholar 

  46. Foss B, Bruserud O. Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost. 2008;99(1):27–37.

    CAS  PubMed  Google Scholar 

  47. Ramos OF, Moron EC, De Castro Arenas R. Platelet function abnormalities in acute leukaemia. Haematologia. 1981;14(4):383–91.

    CAS  PubMed  Google Scholar 

  48. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, et al. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011;9(11):2302–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. White JG, Gerrard JM. Ultrastructural features of abnormal blood platelets. A review. Am J Pathol. 1976;83(3):589–632.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Meschengieser S, Blanco A, Woods A, Maugeri N, Fernandez J, Dupont J, et al. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders. Thromb Res. 1987;48(3):311–9.

    Article  CAS  PubMed  Google Scholar 

  51. Raman BK, Van Slyck EJ, Riddle J, Sawdyk MA, Abraham JP, Saeed SM. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol. 1989;91(6):647–55.

    Article  CAS  PubMed  Google Scholar 

  52. Lintula R, Rasi V, Ikkala E, Borgström GH, Vuopio P. Platelet function in preleukaemia. Scand J Haematol. 1981;26(1):65–71.

    Article  CAS  PubMed  Google Scholar 

  53. Mittelman M, Zeidman A. Platelet function in the myelodysplastic syndromes. Int J Hematol. 2000;71(2):95–8.

    CAS  PubMed  Google Scholar 

  54. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2(8655):122–4.

    Article  CAS  PubMed  Google Scholar 

  55. Bain B, Catovsky D, O’Brien M, Prentice H, Lawlor E, Kumaran T, et al. Megakaryoblastic leukemia presenting as acute myelofibrosis—a study of four cases with the platelet-peroxidase reaction. Blood. 1981;58(2):206–13.

    CAS  PubMed  Google Scholar 

  56. Bevan D, Rose M, Greaves M. Leukaemia of platelet precursors: diverse features in four cases. Br J Haematol. 1982;51(1):147–64.

    Article  CAS  PubMed  Google Scholar 

  57. Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost. 2010;36(4):388–403.

    Article  CAS  PubMed  Google Scholar 

  58. Manoharan A, Brighton T, Gemmell R, Lopez K, Moran S, Kyle P. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. Int J Hematol. 2002;76(3):272–8.

    Article  CAS  PubMed  Google Scholar 

  59. Kerkhofs H, Hagemeijer A, Leeksma CHW, Abels J, Den Ottolaner GJ, Somers R, et al. The 5q- chromosome abnormality in haematological disorders:|a collaborative study of 34 cases from the Netheralands. Br J Haematol. 1982;52(3):365–81.

    Article  CAS  PubMed  Google Scholar 

  60. Mahmood T, Robinson WA, Hamstra RD, Wallner SF. Macrocytic anemia, thrombocytosis and nonlobulated megakaryocytes: the 5q-syndrome, a distinct entity. Am J Med. 1979;66(6):946–50.

    Article  CAS  PubMed  Google Scholar 

  61. Bernstein R, Pinto MR, Behr A, Mendelow B. Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: report of three patients with a “new” inversion anomaly and a further case of homologous translocation. Blood. 1982;60(3):613–7.

    CAS  PubMed  Google Scholar 

  62. Cortelazzo S, Viero P, D’Emilio A, de Gaetano G, Barbui T. Platelet dysfunction in splenectomized patients with hairy cell leukemia. Eur J Cancer Clin Oncol. 1986;22(8):935–7.

    Article  CAS  PubMed  Google Scholar 

  63. Sweet DL, Golomb HM. Correction of platelet defect after splenectomy in hairy cell leukemia. JAMA. 1979;241(16):1684.

    Article  CAS  PubMed  Google Scholar 

  64. Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP. Platelet function in hairy-cell leukaemia. J Clin Pathol. 1979;32(8):814–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Rosove MH, Naeim F, Harwig S, Zighelboim J. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood. 1980;55(6):903–6.

    CAS  PubMed  Google Scholar 

  66. Gedik E, Girgin S, Aldemir M, Keles C, Tuncer MC, Aktas A. Non-traumatic splenic rupture: report of seven cases and review of the literature. World J Gastroenterol. 2008;14(43):6711–6.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Szotkowski T, Szotkowska R, Pikalova Z, Tichy T, Flodr P, Tichy M, et al. Spontaneous splenic rupture in two patients with hematologic malignancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1):113–6.

    Article  PubMed  Google Scholar 

  68. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127(10):1307–16.

    Article  CAS  PubMed  Google Scholar 

  69. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014;28(6):1191–5.

    Article  CAS  PubMed  Google Scholar 

  70. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601–12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

    Article  CAS  PubMed  Google Scholar 

  72. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.

    Article  CAS  PubMed  Google Scholar 

  73. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.

    Article  CAS  PubMed  Google Scholar 

  74. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176–84.

    Article  CAS  PubMed  Google Scholar 

  75. Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Oncol. 1995;22:327–33.

    CAS  PubMed  Google Scholar 

  76. Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood. 1960;15:706.

    CAS  PubMed  Google Scholar 

  77. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549–56.

    Article  CAS  PubMed  Google Scholar 

  78. Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer. 1986;58:2440–7.

    Article  CAS  PubMed  Google Scholar 

  79. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Hematology. 1991:101–6.

    Google Scholar 

  80. Schafer AI. Essential thrombocythemia. Philadephia: W B Saunders; 1991. p. 69–96.

    Google Scholar 

  81. Buss DH, Cashell AW, O’Connor ML, Richards F II, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247–53.

    Article  CAS  PubMed  Google Scholar 

  82. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.

    Article  CAS  PubMed  Google Scholar 

  83. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol. 1998 Sep;5(5):327–31.

    Article  CAS  PubMed  Google Scholar 

  84. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann E, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Schafer AI. Essential Thrombocythemia. In: Coller BS, editor. Progress in hemostasis and thrombosis. Philadephia: W.B. Saunders; 1991. p. 69–96.

    Google Scholar 

  87. Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol. 1983;19:1593–9.

    Article  CAS  PubMed  Google Scholar 

  88. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Myeloproliferative disorders in portal vein thrombosis in adults. Gastroenterology. 1988;94:1063–9.

    Article  CAS  PubMed  Google Scholar 

  89. Najean Y, Mugnier P, Dresch C, Rain JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 1987;67:285–91.

    Article  CAS  PubMed  Google Scholar 

  90. Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–62.

    Article  CAS  PubMed  Google Scholar 

  91. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132–43.

    CAS  PubMed  Google Scholar 

  92. Chievitz E, Thede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172:513–23.

    Article  CAS  PubMed  Google Scholar 

  93. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am J Hematol. 1999;61:10–5.

    Article  CAS  PubMed  Google Scholar 

  94. Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65:132–9.

    Article  CAS  PubMed  Google Scholar 

  95. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123:656–64.

    Google Scholar 

  96. Maugeri N, Malato S, Femia EA, Pugliano M, Campana L, Lunghi F, et al. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. Blood. 2011;118(12):3359–66.

    Article  CAS  PubMed  Google Scholar 

  97. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–51.

    Article  PubMed  Google Scholar 

  98. Landolfi R, Di GL, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22(11):2020–8.

    Article  CAS  PubMed  Google Scholar 

  99. Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116(7):1051–5.

    Article  CAS  PubMed  Google Scholar 

  100. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–66.

    Article  PubMed  Google Scholar 

  101. Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84(4):215–20.

    Article  PubMed  Google Scholar 

  102. Caramazza D, Caracciolo C, Barone R, Malato A, Saccullo G, Cigna V, et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol. 2009;88(10):967–71.

    Article  PubMed  Google Scholar 

  103. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012;2012:571–81.

    PubMed  Google Scholar 

  104. Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients. Am J Hematol. 2016;91(3):318–21.

    Article  PubMed  Google Scholar 

  105. Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:794240.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249–59.

    Article  PubMed  Google Scholar 

  107. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997;56:168–72.

    Article  CAS  PubMed  Google Scholar 

  108. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. Ann Intern Med. 1985;103:329–34.

    Article  CAS  PubMed  Google Scholar 

  109. Reid CDL, Fidler J, Kirk A. Endogenous erythroid clones (EEC) in polycythaemia and their relationship to diagnosis and the response to treatment. Br J Haematol. 1988;68:395–400.

    Article  CAS  PubMed  Google Scholar 

  110. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. Gastroenterology. 1988;94:1063–9.

    Article  CAS  PubMed  Google Scholar 

  111. Petrides PE, Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol Dis. 2006;36(3):379–84.

    Article  CAS  PubMed  Google Scholar 

  112. Lengfelder E, Hochhaus A, Kronawitter U, Hoche D, Queisser W, Jahn-Eder M, et al. Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1997;100:15–23.

    Article  Google Scholar 

  113. Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24(4):900–3.

    Article  CAS  PubMed  Google Scholar 

  114. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009;115(24):5740–5.

    Article  PubMed  Google Scholar 

  115. Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, et al. Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Investig. 2016;46(8):683–9.

    Article  CAS  Google Scholar 

  116. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409–17.

    Article  CAS  PubMed  Google Scholar 

  117. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37(9):1016–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009;94(5):733–7.

    Article  PubMed  PubMed Central  Google Scholar 

  119. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol. 2010;89(2):141–6.

    Article  PubMed  CAS  Google Scholar 

  120. Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood. 2013;122(23):3705–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122(23):3787–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Coucelo M, Caetano G, Sevivas T, Almeida Santos S, Fidalgo T, Bento C, et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol. 2014;99(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  123. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.

    Article  CAS  PubMed  Google Scholar 

  124. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.

    Article  PubMed  Google Scholar 

  125. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediat Inflamm. 2015;2015:284706.

    Article  CAS  Google Scholar 

  126. Michiels JJ. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism—thesis, Rotterdam, 1981. Semin Thromb Hemost. 1997;23:335–8.

    Article  CAS  PubMed  Google Scholar 

  127. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102:466–71.

    Article  CAS  PubMed  Google Scholar 

  128. Singh AK, Wetherley-Mein G. Microvascular occlusive lesions in primary thrombocythaemia. Br J Haematol. 1977;36:553.

    Article  CAS  PubMed  Google Scholar 

  129. Frewin R, Dowson A. Headache in essential thrombocythaemia. Int J Clin Pract. 2012;66(10):976–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984;64:1–12.

    CAS  PubMed  Google Scholar 

  131. Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701–11.

    Article  CAS  PubMed  Google Scholar 

  132. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006;17(8):528–44.

    Article  CAS  PubMed  Google Scholar 

  133. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006;32(3):174–207.

    Article  CAS  PubMed  Google Scholar 

  134. Gilbert HS. The spectrum of myeloproliferative disorders. Med Clin North Am. 1973;57:355.

    Article  CAS  PubMed  Google Scholar 

  135. Silverstein MN. Primary or hemorrhagic thrombocythemia. Arch Intern Med. 1968;122:18.

    Article  CAS  PubMed  Google Scholar 

  136. Spaet TH, Bauer S, Melamed S. Hemorrhagic thrombocythemia: a blood coagulation disorder. Arch Intern Med. 1956;98:377.

    Article  Google Scholar 

  137. Zucker S, Mielke CH. Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications. J Lab Clin Med. 1972;80:385–94.

    CAS  PubMed  Google Scholar 

  138. Preston FE, Emmanuel IG, Winfield DA, Malia RG. Essential thrombocythaemia and peripheral gangrene. Br Med J. 1974;3:548.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Michiels JJ, Koudstaal PJ, Mulder AH, Van Vliet HHDM. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology. 1993;43:1107–10.

    Article  CAS  PubMed  Google Scholar 

  140. Nimer SD. Essential thrombocythemia: another “heterogeneous disease” better understood? Blood. 1999;93:415–6.

    CAS  PubMed  Google Scholar 

  141. Andreasson B, Harrison C, Lindstedt G, Linch D, Kutti J. Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia. Blood. 2003;101(2):783.

    Article  CAS  PubMed  Google Scholar 

  142. Chiusolo P, La Barbera EO, Laurenti L, Piccirillo N, Sora F, Giordano G, et al. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol. 2001;29(6):670–6.

    Article  CAS  PubMed  Google Scholar 

  143. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417–24.

    CAS  PubMed  Google Scholar 

  144. Meschengieser S, Blanco A, Maugeri N, Dupont J, Fernandez J, deTezanos Pinto M, et al. Platelet function and intraplatelet von Willebrand factor antigen and fibrinogen in myelodysplastic syndromes. Thromb Res. 1987;46:601–6.

    Article  CAS  PubMed  Google Scholar 

  145. Cunietti E, Gandini R, Mascaro G, Ferrari M, Pappalepore V, Scapellato L. Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases. Scand J Haematol. 1981;26:339–44.

    Article  CAS  PubMed  Google Scholar 

  146. Givelber AD. Platelet function in patients with high platelet counts. Ann Intern Med. 1975;82:506.

    Article  Google Scholar 

  147. Hehlmann R, Jahn M, Baumann B, Kopcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer. 1988;61:2487–96.

    Article  CAS  PubMed  Google Scholar 

  148. Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med. 1984;103:894–904.

    CAS  PubMed  Google Scholar 

  149. Waddell CC, Brown JA, Repinecz YA. Abnormal platelet function in myeloproliferative disorders. Arch Pathol Lab Med. 1981;105:432–5.

    CAS  PubMed  Google Scholar 

  150. Walsh PN, Murphy S, Barry WE. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thromb Haemost. 1977;38:1085–96.

    CAS  PubMed  Google Scholar 

  151. Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med. 1978;88:7.

    Article  CAS  PubMed  Google Scholar 

  152. Yamamoto K, Sekiguchi E, Takatani O. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemost. 1984;52:292–6.

    CAS  PubMed  Google Scholar 

  153. Boughton BJ, Allington MJ, King A. Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol. 1978;40:125–32.

    Article  CAS  PubMed  Google Scholar 

  154. Cortelazzo S, Barbui T, Bassan R, et al. Abnormal aggregation and increased size of platelets in myeloproliferative disorders. Thromb Haemost. 1980;44:127.

    Google Scholar 

  155. Castaldi PA, Berndt MC, Booth W, Gregory C, Bull H, Greaves M. Evidence for a platelet membrane defect in the myeloproliferative syndromes. Thromb Res. 1982;27:601–9.

    Article  CAS  PubMed  Google Scholar 

  156. Eche N, Sie P, Caranobe C, Nouvel C, Pris J, Boneu B. Platelets in myeloproliferative disorders. III: glycoprotein profile in relation to platelet function and platelet density. Scand J Haematol. 1981;26:123–9.

    Article  CAS  PubMed  Google Scholar 

  157. Moore A, Nachman RL. Platelet Fc receptor: increased expression in myeloproliferative disease. J Clin Invest. 1981;67:1064–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia. Br J Haematol. 1982;51:469–77.

    Article  CAS  PubMed  Google Scholar 

  159. Keenan JP, Wharton J, Shepherd AJN, Bellingham AJ. Defective platelet lipid peroxidation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. Br J Haematol. 1977;35:275–83.

    Article  CAS  PubMed  Google Scholar 

  160. Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med. 1982;306:381–6.

    Article  CAS  PubMed  Google Scholar 

  161. Stenke L, Edenius C, Samuelsson J, Lindgren JA. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood. 1991;78:2989–95.

    CAS  PubMed  Google Scholar 

  162. Rendu F, Lebret M, Nurden A, Caen JP. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemost. 1979;42:794–6.

    CAS  PubMed  Google Scholar 

  163. Woodruff RK, Bell WR, Castaldi PA, et al. Essential thrombocythaemia. Haemostasis. 1980;9:105.

    CAS  PubMed  Google Scholar 

  164. Baker RI, Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol. 1988;40:267–72.

    Article  CAS  PubMed  Google Scholar 

  165. Wehmeier A, Fricke S, Scharf RE, Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol. 1990;45:191–7.

    Article  CAS  PubMed  Google Scholar 

  166. Cardamone JM, Edson JR, McArthur JR, Jacob HS. Abnormalities of platelet function in the myeloproliferative disorders. JAMA. 1972;221:270–3.

    Article  CAS  PubMed  Google Scholar 

  167. Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986;68(6):1213–7.

    CAS  PubMed  Google Scholar 

  168. Raman BKS, Sawdyk M, Saeed SM. Essential thrombocythemia with acquired von Willebrand’s disease. Am J Clin Pathol. 1987;88(1):102–6.

    Article  CAS  PubMed  Google Scholar 

  169. Mohri H, Ohkubo T. Acquired von Willebrand’s syndrome due to an inhibitor of IgG specific for von Willebrand’s factor in polycythemia rubra vera. Acta Haematol. 1987;78(4):258–64.

    Article  CAS  PubMed  Google Scholar 

  170. Boughton BJ. Chronic myeloproliferative disorders: improved platelet aggregation following venesection. Br J Haematol. 1978;39:589–98.

    Article  CAS  PubMed  Google Scholar 

  171. Lee LH, Baglin T. Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. Br J Haematol. 1995;89:131–6.

    Article  CAS  PubMed  Google Scholar 

  172. Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105:618–25.

    Article  CAS  PubMed  Google Scholar 

  173. Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–24.

    Article  CAS  PubMed  Google Scholar 

  174. Burstein SA, Malpass TW, Yee E, Kadin M, Brigden M, Adamson JW, et al. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br J Haematol. 1984;57:383–92.

    Article  CAS  PubMed  Google Scholar 

  175. Berild D, Hasselbalch H, Knudsen J. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders. Scand J Clin Lab Invest. 1987;47:497–501.

    Article  CAS  PubMed  Google Scholar 

  176. Katoh O, Kimura A, Kuramoto A. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol. 1988;27:276–80.

    Article  CAS  PubMed  Google Scholar 

  177. Baglin T. Management of warfarin (coumarin) overdose. Blood Rev. 1998;12(2):91–8.

    Article  CAS  PubMed  Google Scholar 

  178. Shamasunder HK, Gregory SA, Knospe WH. Uracil mustard in the treatment of thrombocytosis. JAMA. 1980;244:1454–5.

    Article  CAS  PubMed  Google Scholar 

  179. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2):102–8.

    Article  CAS  PubMed  Google Scholar 

  180. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32(6):589–604.

    Article  CAS  PubMed  Google Scholar 

  181. Gisslinger H, Rodeghiero F, Ruggeri M, Fard NHV, Mannhalter C, Papagiannopoulos M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 1999;105:551–5.

    Article  CAS  PubMed  Google Scholar 

  182. Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Am J Hematol. 2000;65:136–40.

    Article  CAS  PubMed  Google Scholar 

  183. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19(3):617–33.

    Article  CAS  PubMed  Google Scholar 

  184. Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061–8.

    Article  CAS  PubMed  Google Scholar 

  185. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169–75.

    CAS  PubMed  Google Scholar 

  186. Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143–51.

    Article  CAS  PubMed  Google Scholar 

  187. Kornberg A, Rahimi-Levene N, Yona R, Mor A, Rachmilewitz EA. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment 1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol. 1997;56:5–11.

    Article  CAS  PubMed  Google Scholar 

  188. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–6.

    CAS  PubMed  Google Scholar 

  189. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205–10.

    Article  CAS  PubMed  Google Scholar 

  191. Pagliuca A, Mufti GJ, Janossa-Tahernia M, Eridani S, Westwood NB, Thumpston J, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis—possible evidence of an occult myeloproliferative state. Q J Med. 1990;281:981–9.

    Google Scholar 

  192. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063–9.

    Article  CAS  PubMed  Google Scholar 

  193. Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113(22):5617–23.

    Article  CAS  PubMed  Google Scholar 

  194. Goldstein R, Clark P, Klintmalm G, Husberg B, Gonwa T, Stone M. Prevention of recurrent thrombosis following liver transplantation for Budd-Chiari syndrome associated with myeloproliferative disorders: treatment with hyddroxyurea and aspirin. Transplant Proc. 1991;23:1559–60.

    CAS  PubMed  Google Scholar 

  195. Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE. Liver transplantation for the Budd-Chiari syndrome. Ann Surg. 1990;211:43–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. van Genderen PJJ, Michiels JJ, van Strik R, Lindemans J, Van Vliet HHDM. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost. 1995;73:210–4.

    PubMed  Google Scholar 

  197. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97:179–84.

    Article  PubMed  Google Scholar 

  198. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.

    Article  CAS  PubMed  Google Scholar 

  199. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97–105.

    Article  PubMed  Google Scholar 

  200. DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA. 2016;315(20):2232.

    Article  PubMed  Google Scholar 

  201. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011;118(5):1359–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Goodnight SH. Antiplatelet therapy with aspirin: from clinical trials to practice. Thromb Haemost. 1995;74:401–5.

    CAS  PubMed  Google Scholar 

  203. Haogland HC, Silverstein MN. Primary thrombocythemia in the young patient. Mayo Clin Proc. 1978;53:578.

    Google Scholar 

  204. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772–7.

    Article  CAS  PubMed  Google Scholar 

  205. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–4.

    Article  CAS  PubMed  Google Scholar 

  206. Choi CW, Bang SM, Jang S, Jung CW, Kim HJ, Kim HY, et al. Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med. 2015;30(6):771–88.

    Article  PubMed  PubMed Central  Google Scholar 

  207. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132–6.

    Article  CAS  PubMed  Google Scholar 

  208. Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost. 2010;104(1):151–6.

    Article  CAS  PubMed  Google Scholar 

  209. Spencer CM, Brogden RN. Anagrelide. A reivew of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs. 1994;47:809–22.

    Article  CAS  PubMed  Google Scholar 

  210. Group AS. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69–76.

    Article  Google Scholar 

  211. Silverstein MN, Petitt RM, Solber LA, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988;318:1292–4.

    Article  CAS  PubMed  Google Scholar 

  212. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863–6.

    Article  CAS  PubMed  Google Scholar 

  213. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis. 1998;24:9–13.

    Article  CAS  PubMed  Google Scholar 

  214. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33–45.

    Article  CAS  PubMed  Google Scholar 

  215. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol. 1994;91:126–9.

    Article  CAS  PubMed  Google Scholar 

  216. Ludwig H, Linkesch W, Gisslinger H, Fritz E, Sinzinger H, Radaszkiewicz T, et al. Interferon-alpha corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother. 1987;25:266–73.

    Article  CAS  PubMed  Google Scholar 

  217. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106(11):2397–405.

    Article  CAS  PubMed  Google Scholar 

  218. Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;98(1):100–9.

    Article  CAS  PubMed  Google Scholar 

  219. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–73.

    Article  CAS  PubMed  Google Scholar 

  220. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  221. Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis. 2014;

    Google Scholar 

  222. Keohane C, McLornan DP, Sanchez K, Connor C, Radia D, Harrison CN. The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms. Haematologica. 2015;100(9):e348–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  223. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9.

    Article  CAS  PubMed  Google Scholar 

  224. Shpilberg O, Shimon I, Sofer O, Dolitski M, Ben-Bassat I. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia. Br J Haematol. 1996;92:491–3.

    Article  CAS  PubMed  Google Scholar 

  225. Wright CA, Tefferi A. A single institutional experience with 43 preganancies in essential thrombocythemia. Eur J Haematol. 2001;66:152–9.

    Article  CAS  PubMed  Google Scholar 

  226. Bangerter M, Guthner C, Beneke H, Hildebrand A, Grunewald M, Griesshammer M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol. 2000;65:165–9.

    Article  CAS  PubMed  Google Scholar 

  227. Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am J Hematol. 2009;84(10):636–40.

    Article  PubMed  Google Scholar 

  228. Lavi N, Brenner B, Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thromb Res. 2013;131(Suppl 1):S11–3.

    Article  CAS  PubMed  Google Scholar 

  229. Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations. Am J Hematol. 2009;84(10):629–30.

    Article  PubMed  Google Scholar 

  230. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82(5):350–3.

    Article  PubMed  Google Scholar 

  231. Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010;8(2):411–3.

    Article  CAS  PubMed  Google Scholar 

  232. Randi ML, Bertozzi I, Rumi E, Elena C, Finazzi G, Vianelli N, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014;89(3):306–9.

    Article  PubMed  Google Scholar 

  233. Bessler M, Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2008;1:104–10.

    Google Scholar 

  234. Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol. 2011;153(6):709–20.

    Article  PubMed  Google Scholar 

  235. Ray J, Burows R, Ginsberg J, Burrows E. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Pathophysiol Haemost Thromb. 2000;30(3):103–17.

    Article  CAS  Google Scholar 

  236. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–96.

    Article  CAS  PubMed  Google Scholar 

  237. Poulou LS, Xila V, Rokas GI, Karianakis G, Bartzoudis D, Ziakas PD. Temporal trends in mortality rates from visceral vein thrombosis in paroxysmal nocturnal haemoglobinuria: an optimistic view. Thromb Haemost. 2008;99(3):642–5.

    CAS  PubMed  Google Scholar 

  238. Murad SD, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167–75.

    Article  Google Scholar 

  239. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126(1):133–8.

    Article  CAS  PubMed  Google Scholar 

  240. Gralnick HR, Vail M, McKeown LP, Merryman P, Wilson O, Chu I, et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;91(3):697–702.

    Article  CAS  PubMed  Google Scholar 

  241. Wiedmer T, Hall S, Ortel T, Kane W, Rosse W, Sims P. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82(4):1192–6.

    CAS  PubMed  Google Scholar 

  242. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794–802.

    Article  CAS  PubMed  Google Scholar 

  243. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.

    Article  CAS  PubMed  Google Scholar 

  244. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–8.

    Article  CAS  PubMed  Google Scholar 

  245. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102(10):3587–91.

    Article  CAS  PubMed  Google Scholar 

  246. Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost. 2007;33(4):339–49.

    Article  PubMed  Google Scholar 

  247. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol. 2009;145(2):151–63.

    Article  PubMed  Google Scholar 

  248. Eby C, Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep. 2003;2(5):388–94.

    PubMed  Google Scholar 

  249. Perkins HA, Mackenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. Blood. 1970;35(5):695–707.

    CAS  PubMed  Google Scholar 

  250. Niléhn J-E, Nilsson IM. Coagulation studies in different types of myeloma. Acta Med Scand. 1966;179(S445):194–9.

    Article  Google Scholar 

  251. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, Siakantaris P, Kontopidou FN, Dimopoulou MN, et al. Waldenstrom’s macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol. 2001;80(12):722–7.

    Article  CAS  PubMed  Google Scholar 

  252. Eby CS. Bleeding and thrombosis risks in plasma cell dyscrasias. Hematology Am Soc Hematol Educ Program. 2007;2007(1):158–64.

    Google Scholar 

  253. Lackner H, Hunt V, Zucker MB, Pearson J. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma*. Br J Haematol. 1970;18(6):625–36.

    Article  CAS  PubMed  Google Scholar 

  254. Coleman M, Vigliano EM, Weksler ME, Nachman RL. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood. 1972;39(2):210–23.

    CAS  PubMed  Google Scholar 

  255. Davey F, Gordon G, Boral L, Gottlieb A. Gamma globulin inhibition of fibrin clot formation. Ann Clin Lab Sci. 1976;6(1):72–7.

    CAS  PubMed  Google Scholar 

  256. Klingemann HG, Egbring R, Havemann K. Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma. Scand J Haematol. 1981;27(4):253–62.

    Article  CAS  PubMed  Google Scholar 

  257. Soria J, Soria C, Samama M, Fine JM, Bousser J. Analysis of a fibrin formation abnormality in a case of multiple myeloma. Scand J Haematol. 1975;15(3):207–18.

    Article  CAS  PubMed  Google Scholar 

  258. Kaufman PA, Gockerman JP, Greenberg CS. Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. Am J Med. 1989;86(5):612–6.

    Article  CAS  PubMed  Google Scholar 

  259. Kasturi JSA. Platelet functions in dysproteinemia. Acta Haematol. 1978;59:104–13.

    Article  CAS  PubMed  Google Scholar 

  260. DiMinno G, Coraggio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Investig. 1986;77(1):157–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  261. Djunic I, Elezovic I, Ilic V, Tomin D, Suvajdzic-Vukovic N, Bila J, et al. Acquired von Willebrand syndrome in multiple myeloma. Hematology. 2011;16(4):209–12.

    Article  CAS  PubMed  Google Scholar 

  262. Federici AB, Mannucci PM. Diagnosis and management of acquired von Willebrand syndrome. Clin Adv Hematol Oncol. 2003;1(3):169–75.

    PubMed  Google Scholar 

  263. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol. 2007;82(5):368–75.

    Article  CAS  PubMed  Google Scholar 

  264. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U, et al. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost. 2006;32(6):577–88.

    Article  CAS  PubMed  Google Scholar 

  265. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117(25):6777–85.

    Article  CAS  PubMed  Google Scholar 

  266. O’Kane MJ, Wisdom GB, Desai ZR, Archbold GP. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. J Clin Pathol. 1994;47(3):266–8.

    Article  PubMed  PubMed Central  Google Scholar 

  267. Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol. 1999;62(2):99–102.

    Article  CAS  PubMed  Google Scholar 

  268. Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol. 1996;51(4):319–23.

    Article  CAS  PubMed  Google Scholar 

  269. Gruber A, Blasko G, Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res. 1986;42(4):579–81.

    Article  CAS  PubMed  Google Scholar 

  270. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13(3):187–92.

    Article  CAS  PubMed  Google Scholar 

  271. Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  272. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  273. Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006;47(6):947–55.

    Article  CAS  PubMed  Google Scholar 

  274. Mumford AD, O’Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110(2):454–60.

    Article  CAS  PubMed  Google Scholar 

  275. Gamba G, Montani N, Anesi E, Palladini G, Capezzera M, Soldavini E, et al. Clotting alterations in primary systemic amyloidosis. Haematologica. 2000;85(3):289–92.

    CAS  PubMed  Google Scholar 

  276. Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis. N Engl J Med. 1977;297(2):81–5.

    Article  CAS  PubMed  Google Scholar 

  277. Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885–7.

    Article  CAS  PubMed  Google Scholar 

  278. Camoriano JK, Greipp PR, Bayer GK, Bowie EJ. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med. 1987;316(18):1133–5.

    Article  CAS  PubMed  Google Scholar 

  279. Rosenstein ED, Itzkowitz SH, Penziner AS, Cohen JI, Mornaghi RA. REsolution of factor x deficiency in primary amyloidosis following splenectomy. Arch Intern Med. 1983;143(3):597–9.

    Article  CAS  PubMed  Google Scholar 

  280. Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010;85(3):171–3.

    PubMed  PubMed Central  Google Scholar 

  281. Shigekiyo T, Kosaka M, Shintani Y, Azuma H, Iishi Y, Saito S. Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis. Acta Haematol. 1989;81(3):160–5.

    Article  CAS  PubMed  Google Scholar 

  282. Glueck HI, Coots MC, Benson M, Dwulet FE, Hurtubise PE. A monoclonal immunoglobulin A (kappa) factor VIII:C inhibitor associated with primary amyloidosis: identification and characterization. J Lab Clin Med. 1989;113(3):269–77.

    CAS  PubMed  Google Scholar 

  283. Liebman H, Chinowsky M, Valdin J, Kenoyer G, Feinstein D. INcreased fibrinolysis and amyloidosis. Arch Intern Med. 1983;143(4):678–82.

    Article  CAS  PubMed  Google Scholar 

  284. Meyer K, Williams EC. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med. 1985;79(3):394–6.

    Article  CAS  PubMed  Google Scholar 

  285. Liebman HA, Carfagno MK, Weitz IC, Berard P, Diiorio JM, Vosburgh E, et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol. 1992;98(5):534–41.

    Article  CAS  PubMed  Google Scholar 

  286. Uchiba M, Imamura T, Hata H, Tatetsu H, Yonemura Y, Ueda M, et al. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid. 2009;16(2):89–93.

    Article  CAS  PubMed  Google Scholar 

  287. Takahashi H, Koike T, Yoshida N, Kitahara O, Hanano M, Shibata A, et al. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol. 1986;23(2):153–66.

    Article  CAS  PubMed  Google Scholar 

  288. Sane DC, Pizzo SV, Greenberg CS. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. Am J Hematol. 1989;31(1):53–7.

    Article  CAS  PubMed  Google Scholar 

  289. Chang JC, Kane KK. Pathologic hyperfibrinolysis associated with amyloidosis: clinical response to epsilon amino caproic acid. Am J Clin Pathol. 1984;81(3):382–7.

    Article  CAS  PubMed  Google Scholar 

  290. Hamilton PJ, Dawson AA. Thrombocytopenic purpura as the sole manifestation of a recurrence of Hodgkin’s disease. J Clin Pathol. 1973;26(1):70–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  291. Waddell CC, Cimo PL. Idiopathic thrombocytopenic purpura occurring in Hodgkin disease after splenectomy: report of two cases and review of the literature. Am J Hematol. 1979;7(4):381–7.

    Article  CAS  PubMed  Google Scholar 

  292. Murphy WG, Allan NC, Perry DJ, Stockdill G. Hodgkin’s disease presenting as idiopathic thrombocytopenic purpura. Postgrad Med J. 1984;60(707):614–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  293. Rudders RA, Aisenberg AC, Schiller AL. Hodgkin’s disease presenting as “idiopathic” thrombocytopenic purpura. Cancer. 1972;30(1):220–30.

    Article  CAS  PubMed  Google Scholar 

  294. Khilanani R, al-Sarraf M. The association of autoimmune thrombocytopenia and Hodgkin’s disease. Oncology. 1973;28(3):238–45.

    Article  CAS  PubMed  Google Scholar 

  295. Hassidim K, McMillan R, Conjalka MS, Morrison J. Immune thrombocytopenic purpura in Hodgkin disease. Am J Hematol. 1979;6(2):149–53.

    Article  CAS  PubMed  Google Scholar 

  296. Berkman AW, Woog JJ, Kickler TS, Ettinger DS. Serial determinations of antiplatelet antibodies in a patient with Hodgkin’s disease and autoimmune thrombocytopenia. Cancer. 1983;51(11):2057–60.

    Article  CAS  PubMed  Google Scholar 

  297. Kaden B, Rosse W, Hauch T. Immune thrombocytopenia in lymphoproliferative diseases. Blood. 1979;53(4):545–51.

    CAS  PubMed  Google Scholar 

  298. Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenic purpura and Hodgkin’s disease: report of two cases and a review of the literature. Am J Med Sci. 1980;280(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  299. Kemplin SJ. Late hematologic complications after treatment of Hodgkin’s disease. In: Lacher MJ, Redman JR, editors. Hodgkin’s disease: the consequences of survival. Philadelphia/London: Lea & Febiger; 1990. p. 63.

    Google Scholar 

  300. Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann’s thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom. 2008;74B(3):194–9.

    Article  CAS  Google Scholar 

  301. Malik U, Dutcher JP, Oleksowicz L. Acquired glanzmann’s thrombasthenia associated with hodgkin’s lymphoma. Cancer. 1998;82(9):1764–8.

    Article  CAS  PubMed  Google Scholar 

  302. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL): changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50(8):1261–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  303. Karpatkin S. Autoimmune thrombocytopenic purpura. Blood. 1980;56(3):329–43.

    CAS  PubMed  Google Scholar 

  304. Berrang T, Holloway C, Hart J, Yee A, Berry B, Kotb R. Successful treatment of non-Hodgkin lymphoma associated immune thrombocytopenia with involved field radiotherapy. Hematol Oncol. 2013;31(4):218–20.

    Article  PubMed  Google Scholar 

  305. Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009;46(1 Suppl 2):S33–S6.

    Article  PubMed  Google Scholar 

  306. Olson SR, Chu C, Shatzel JJ, Deloughery TG. The “platelet boilermaker”: a treatment protocol to rapidly increase platelets in patients with immune-mediated thrombocytopenia. Am J Hematol. 2016;91(8):E330–E1.

    Article  PubMed  Google Scholar 

  307. Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004.

    Article  CAS  PubMed  Google Scholar 

  308. Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard J, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84(10):661–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  309. George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994;331(18):1207–11.

    Article  CAS  PubMed  Google Scholar 

  310. Reiner A, Gernsheimer T, Slichter S. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351–8.

    CAS  PubMed  Google Scholar 

  311. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.

    Article  CAS  PubMed  Google Scholar 

  312. Cooper N, Terrinoni I, Newland A. The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia. Ther Adv Hematol. 2012;3(5):291–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  313. Julia A, Miller SP. Idiopathic thrombocytopenic purpura in hodgkin’s disease after splenectomy. Am J Hematol. 1976;1(1):115–20.

    Article  CAS  PubMed  Google Scholar 

  314. Kedar A, Khan AB, Mattern Ii JQA, Fisher J, Thomas PRM, Freeman AI. Autoimmune disorders complicating adolescent hodgkin’s disease. Cancer. 1979;44(1):112–6.

    Article  CAS  PubMed  Google Scholar 

  315. Fink K, Al-Mondhiry H. Idiopathic thrombocytopenic purpura in lymphoma. Cancer. 1976;37(4):1999–2004.

    Article  CAS  PubMed  Google Scholar 

  316. Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997;103(6):536–40.

    Article  CAS  PubMed  Google Scholar 

  317. Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;6(4):565–8.

    Article  CAS  PubMed  Google Scholar 

  318. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol. 2001;14(2):401–36.

    Article  CAS  PubMed  Google Scholar 

  319. Facon T, Caron C, Courtin P, Wurtz A, Deghaye M, Bauters F, et al. Acquired type II von Willebrand’s disease associated with adrenal cortical carcinoma. Br J Haematol. 1992;80(4):488–94.

    Article  CAS  PubMed  Google Scholar 

  320. Mannucci P, Lombardi R, Bader R, Horellou M, Finazzi G, Besana C, et al. Studies of the pathophysiology of acquired von Willebrand’s disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood. 1984;64(3):614–21.

    CAS  PubMed  Google Scholar 

  321. Fricke W, Brinkhous K, Garris J, Roberts H. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood. 1985;66(3):562–9.

    CAS  PubMed  Google Scholar 

  322. van Genderen P, Vink T, Michiels J, van ‘t Veer M, Sixma J, van Vliet H. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood. 1994;84(10):3378–84.

    PubMed  Google Scholar 

  323. Handin R, Martin V, Moloney W. Antibody-induced von Willebrand’s disease: a newly defined inhibitor syndrome. Blood. 1976;48(3):393–405.

    CAS  PubMed  Google Scholar 

  324. Joist JH, Cowan JF, Zimmerman TS. Acquired von Willebrand’s disease. N Engl J Med. 1978;298(18):988–91.

    Article  CAS  PubMed  Google Scholar 

  325. Richard C, Cuadrado MA, Prieto M, Batlle J, Lopez Fernandez MF, Rodriguez Salazar ML, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol. 1990;35(2):114–7.

    Article  CAS  PubMed  Google Scholar 

  326. Guerin V, Ryman A, Velez F. Acquired von Willebrand disease: potential contribution of the von Willebrand factor collagen-binding to the identification of functionally inhibiting auto-antibodies to von Willebrand factor: a rebuttal. J Thromb Haemost. 2008;6(6):1051–2.

    Article  CAS  PubMed  Google Scholar 

  327. Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand’s disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol. 1997;96(4):850–3.

    Article  CAS  PubMed  Google Scholar 

  328. Silberstein LE, Abrahm J, Shattil SJ. The efficacy of intensive plasma exchange in acquired von Willebrand’s disease. Transfusion. 1987;27(3):234–7.

    Article  CAS  PubMed  Google Scholar 

  329. White LA, Chisholm M. Gastro-intestinal bleeding in acquired von Willebrand’s disease: efficacy of high-dose immuno-globulin where substitution treatments failed. Br J Haematol. 1993;84(2):332–4.

    Article  CAS  PubMed  Google Scholar 

  330. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84(2):345–9.

    CAS  PubMed  Google Scholar 

  331. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood. 1998;92(8):2707–11.

    CAS  PubMed  Google Scholar 

  332. Delmer A, Horellou MH, Bréchot JM, Prudent J, Potevin F, Lecrubier C, et al. Acquired von willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol. 1992;40(2):151–2.

    Article  CAS  PubMed  Google Scholar 

  333. Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinolysis. 2006;17(8):615–9.

    Article  CAS  PubMed  Google Scholar 

  334. Friederich PW, Wever PC, Briët E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol. 2001;66(4):292–4.

    Article  CAS  PubMed  Google Scholar 

  335. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood. 1998;91(10):3623–9.

    CAS  PubMed  Google Scholar 

  336. Wenz B, Friedman G. Acquired factor VIII inhibitor in a patient with malignant lymphoma. Am J Med Sci. 1974;268(5):295–9.

    Article  CAS  PubMed  Google Scholar 

  337. Castaldi PA, Penny R. A macroglobulin with inhibitory activity against coagulation factor VIII. Blood. 1970;35(3):370–6.

    CAS  PubMed  Google Scholar 

  338. Lee ES, Hibsman BK, Liebman HA. Acquired bleeding disorder in a patient with malignant lymphoma. Cancer. 2001;91(4):636–41.

    Article  CAS  PubMed  Google Scholar 

  339. Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol. 1997;97(1):219–26.

    Article  CAS  PubMed  Google Scholar 

  340. Hanley D, Arkel YS, Lynch J, Kamiyama M. Acquired von Willebrand’s syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin. Am J Hematol. 1994;46(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  341. Bussel JB, Steinherz PG, Miller DR, Hilgartner MW. A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia. Am J Hematol. 1984;16(1):83–90.

    Article  CAS  PubMed  Google Scholar 

  342. Khoory MS, Nesheim ME, Bowie EJ, Mann KG. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Investig. 1980;65(3):666–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  343. Tefferi A, Nichols WL, Bowie EJ. Circulating heparin-like anticoagulants: report of five consecutive cases and a review. Am J Med. 1990;88(2):184–8.

    Article  CAS  PubMed  Google Scholar 

  344. Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982;4(3):335–9.

    CAS  PubMed  Google Scholar 

  345. Sills RH, Nelson DA, Stockman JA. L-asparaginase-induced coagulopathy during therapy of acute lymphocytic leukemia. Med Pediatr Oncol. 1978;4(4):311–3.

    Article  CAS  PubMed  Google Scholar 

  346. Anderson N, Lokich JJ, Tullis JL. L-asparaginase effect on antithrombin-III levels. Med Pediatr Oncol. 1979;7(4):335–40.

    Article  CAS  PubMed  Google Scholar 

  347. Barbui T, Finazzi G, Vigano S, Mannucci PM. L-asparaginase lowers protein C antigen. Thromb Haemost. 1984;52(2):216.

    CAS  PubMed  Google Scholar 

  348. Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr. 1986;108(5 Pt 1):698–701.

    Article  CAS  PubMed  Google Scholar 

  349. Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol. 1980;8(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  350. Conard J, Horellou MH, Van Dreden P, Potevin F, Zittoun R, Samama M. Decrease in protein C in L-asparaginase-treated patients. Br J Haematol. 1985;59(4):725–7.

    Article  CAS  PubMed  Google Scholar 

  351. Gralnick HR, Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer. 1971;27(6):1313–20.

    Article  CAS  PubMed  Google Scholar 

  352. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol. 1987;5(5):811–7.

    Article  CAS  PubMed  Google Scholar 

  353. Hernández-Espinosa D, Miñano A, Martínez C, Pérez-Ceballos E, Heras I, Fuster JL, et al. l-Asparaginase-induced antithrombin type I deficiency : implications for conformational diseases. Am J Pathol. 2006;169(1):142–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  354. Pui CH, Jackson CW, Chesney C, Lyles SA, Bowman WP, Abromowitch M, et al. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine. J Clin Oncol. 1983;1(6):380–5.

    Article  CAS  PubMed  Google Scholar 

  355. Ramsay NKC, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase on plasma coagulation factors in acute lymphoblastic leukemia. Cancer. 1977;40(4):1398–401.

    Article  CAS  PubMed  Google Scholar 

  356. Bettigole RE, Himelstein ES, Oettgen HF, Clifford GO. Hypofibrinogenemia due to L-Asparaginase: studies of fibrinogen survival using autologous 131I-fibrinogen. Blood. 1970;35(2):195–200.

    CAS  PubMed  Google Scholar 

  357. Nowak-Göttl U, Ahlke E, Klösel K, Jürgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr. 1997;156(11):848–50.

    Article  PubMed  Google Scholar 

  358. Groopman J, Ellman L. Acute promyelocytic leukemia. Am J Hematol. 1979;7(4):395–408.

    Article  CAS  PubMed  Google Scholar 

  359. Sultan C, Heilmann-Gouault M, Tulliez M. Relationship between blast-cell morphology and occurrence of a syndrome of disseminated intravascular coagulation. Br J Haematol. 1973;24(2):255–9.

    Article  CAS  PubMed  Google Scholar 

  360. Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 1982;50(3):451–6.

    Article  CAS  PubMed  Google Scholar 

  361. Pui C-H, Jackson CW, Chesney CM, Abildgaard CF. Involvement of von willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol. 1987;25(3):291–8.

    Article  CAS  PubMed  Google Scholar 

  362. Bauer KA, Teitel JM, Rosenberg RD. L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res. 1983;29(4):437–42.

    Article  CAS  PubMed  Google Scholar 

  363. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–9.

    Article  PubMed  PubMed Central  Google Scholar 

  364. Priest JR, Ramsay NK, Steinherz PG, Tubergen DG, Cairo MS, Sitarz AL, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100(6):984–9.

    Article  CAS  PubMed  Google Scholar 

  365. Pui CH, Chesney CM, Bergum PW, Jackson CW, Rapaport SI. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol. 1986;64(2):283–90.

    Article  CAS  PubMed  Google Scholar 

  366. Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol. 1992;49(2):63–6.

    Article  CAS  PubMed  Google Scholar 

  367. Urban C, Sager WD. Intracranial bleeding during therapy with L-asparaginase in childhood acute lymphocytic leukemia. Eur J Pediatr. 1981;137(3):323–7.

    Article  CAS  PubMed  Google Scholar 

  368. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216–22.

    Article  CAS  PubMed  Google Scholar 

  369. Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93(5):1595–9.

    CAS  PubMed  Google Scholar 

  370. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83(6):840–3.

    CAS  PubMed  Google Scholar 

  371. Steinherz PG, Miller LP, Ghavimi F, Allen JC, Miller DR. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA. 1981;246(24):2837–9.

    Article  CAS  PubMed  Google Scholar 

  372. Hunault-Berger M, Chevallier P, Delain M, Bulabois C-E, Bologna S, Bernard M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93(10):1488–94.

    Article  CAS  PubMed  Google Scholar 

  373. Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010;115(24):4999–5004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  374. Quintás-Cardama A, Kantarjian H, Ravandi F, O’Brien S, Thomas D, Vidal-Senmache G, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115(11):2482–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  375. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  376. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  377. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  378. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  379. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.

    Article  CAS  PubMed  Google Scholar 

  380. Quek LS, Bolen J, Watson SP. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8(20):1137–40.

    Article  CAS  PubMed  Google Scholar 

  381. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783–7.

    Article  CAS  PubMed  Google Scholar 

  382. Levade M, David E, Garcia C, Laurent P-A, Cadot S, Michallet A-S, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991–5.

    Article  CAS  PubMed  Google Scholar 

  383. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  384. Antimicrobials and haemostasis. Lancet. 1983;1(8323):510–1.

    Google Scholar 

  385. Sattler FR, Weitekamp MR, Sayegh A, Ballard JO. Impaired hemostasis caused by beta-lactam antibiotics. Am J Surg. 1988;155(5a):30–9.

    Article  CAS  PubMed  Google Scholar 

  386. Andrassy K, Weischedel E, Ritz E, Andrassy T. Bleeding in uremic patients after carbenicillin. Thromb Haemost. 1976;36(1):115–26.

    CAS  PubMed  Google Scholar 

  387. Bang NU, Tessler SS, Heidenreich RO, Marks CA, Mattler LE. Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis. 1982;4(Suppl):S546–54.

    Article  PubMed  Google Scholar 

  388. Brown CH 3rd, Natelson EA, Bradshaw W, Williams TW Jr, Alfrey CP Jr. The hemostatic defect produced by carbenicillin. N Engl J Med. 1974;291(6):265–70.

    Article  CAS  PubMed  Google Scholar 

  389. Haburchak DR, Head DR, Everett ED. Postoperative hemorrhage associated with carbenicillin administration. Report of two cases and review of the literature. Am J Surg. 1977;134(5):630–4.

    Article  CAS  PubMed  Google Scholar 

  390. Johnson GJ, Rao GH, White JG. Platelet dysfunction induced by parenteral carbenicillin and ticarcillin. Studies of the dose-response relationship and mechanism of action in dogs. Am J Pathol. 1978;91(1):85–106.

    CAS  PubMed  PubMed Central  Google Scholar 

  391. Shevchuk YM, Conly JM. Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966–1988. Rev Infect Dis. 1990;12(6):1109–26.

    Article  CAS  PubMed  Google Scholar 

  392. Matsubara T, Touchi A, Harauchi T, Takano K, Yoshizaki T. Depression of liver microsomal vitamin K epoxide reductase activity associated with antibiotic-induced coagulopathy. Biochem Pharmacol. 1989;38(16):2693–701.

    Article  CAS  PubMed  Google Scholar 

  393. Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med. 1986;105(6):924–31.

    Article  CAS  PubMed  Google Scholar 

  394. Pakter RL, Russell TR, Mielke C, West D. Coagulopathy associated with the use of moxalactam. JAMA. 1982;248(9):–1100.

    Google Scholar 

  395. Aziz F, Patil P. Role of prophylactic vitamin K in preventing antibiotic induced hypoprothrombinemia. Indian J Pediatr. 2015;82(4):363–7.

    Article  PubMed  Google Scholar 

  396. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115(11):849–59.

    Article  CAS  PubMed  Google Scholar 

  397. Conly J, Suttie J, Reid E, Loftson J, Ramotar K, Louie T. Dietary deficiency of phylloquinone and reduced serum levels in febrile neutropenic cancer patients. Am J Clin Nutr. 1989;50(1):109–13.

    Article  CAS  PubMed  Google Scholar 

  398. Pegram PS, Phair JP, McMahan R, Murphy RL, Gordon LI, Washton H, et al. Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. J Antimicrob Chemother. 1989;24(4):591–604.

    Article  CAS  PubMed  Google Scholar 

  399. Weitekamp MR, Aber RC. PRolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983;249(1):69–71.

    Article  CAS  PubMed  Google Scholar 

  400. Brown CH 3rd, Natelson EA, Bradshaw MW, Alfrey CP Jr, Williams TW Jr. Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother. 1975;7(5):652–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  401. Natelson EA, Siebert WT, Williams TW, Bradshaw MW. Combined effects of ticarcillin and cefazolin on blood coagulation and platelet function. Am J Med Sci. 1979;278(3):217–21.

    Article  CAS  PubMed  Google Scholar 

  402. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–7.

    Article  PubMed  Google Scholar 

  403. Johansen ME, Jensen J-U, Bestle MH, Hein L, Lauritsen AØ, Tousi H, et al. The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. PLoS One. 2013;8(11):e81477.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  404. Zenon GJ, Cadle RM, Hamill RJ. VAncomycin-induced thrombocytopenia. Arch Intern Med. 1991;151(5):995–6.

    Article  CAS  PubMed  Google Scholar 

  405. Shaik S, Kazi HA, Ender PT. Rapid-onset piperacillin-tazobactam induced thrombocytopenia. J Pharm Pract. 2015;28(2):204–6.

    Article  PubMed  Google Scholar 

  406. Starr JA, Ragucci KR. Thrombocytopenia associated with intravenous ciprofloxacin. Pharmacotherapy. 2005;25(7):1030–4.

    Article  PubMed  Google Scholar 

  407. Christie DJ, van Buren N, Lennon SS, Putnam JL. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with leukemia. Blood. 1990;75(2):518–23.

    CAS  PubMed  Google Scholar 

  408. Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007;356(9):904–10.

    Article  Google Scholar 

  409. Chan CSP, Tuazon CU, Lessin LS. Amphotericin-B-induced thrombocytopenia. Ann Intern Med. 1982;96(3):332–3.

    Article  CAS  PubMed  Google Scholar 

  410. Mercurio MG, Elewski BE. Thrombocytopenia caused by fluconazole therapy. J Am Acad Dermatol. 1995;32(3):525–6.

    Article  CAS  PubMed  Google Scholar 

  411. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555–68.

    Article  CAS  PubMed  Google Scholar 

  412. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65(7–8):677–9.

    CAS  PubMed  Google Scholar 

  413. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318(7):404–7.

    Article  CAS  PubMed  Google Scholar 

  414. Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016;127(7):849–57; quiz 953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  415. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985;42(5):296–300.

    Article  CAS  PubMed  Google Scholar 

  416. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988;6(2):276–81.

    Article  PubMed  Google Scholar 

  417. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Investig. 1996;75(2):281–9.

    CAS  PubMed  Google Scholar 

  418. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189–204.

    Article  CAS  PubMed  Google Scholar 

  419. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343(8902):886–9.

    Article  CAS  PubMed  Google Scholar 

  420. Menon SP, Rajkumar V, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer. 2008;112(7):1522–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  421. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.

    Article  CAS  PubMed  Google Scholar 

  422. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–93.

    Article  CAS  PubMed  Google Scholar 

  423. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005;31(6):681–90.

    Article  CAS  PubMed  Google Scholar 

  424. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am. 10(2):485–97.

    Google Scholar 

  425. Gharpure VS, Devine SM, Holland HK, Geller RB, O’Toole K, Wingard JR. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant. 1995;16(5):715–6.

    CAS  PubMed  Google Scholar 

  426. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–66.

    Article  CAS  PubMed  Google Scholar 

  427. Shah G, Yamin H, Smith H. Mitomycin-C-induced TTP/HUS treated successfully with rituximab: case report and review of the literature. Case Rep Hematol. 2013;2013:130978.

    PubMed  PubMed Central  Google Scholar 

  428. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 2007;8(7):634–41.

    Article  CAS  PubMed  Google Scholar 

  429. Kasi PM. Thrombotic thrombocytopenic purpura and gemcitabine. Case Rep Oncol. 2011;4(1):143–8.

    Article  PubMed  PubMed Central  Google Scholar 

  430. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002;40(4):E16.

    Article  PubMed  Google Scholar 

  431. Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol. 2014;5(1):E30–3.

    PubMed  PubMed Central  Google Scholar 

  432. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer. 1994;74(11):3059–62.

    Article  CAS  PubMed  Google Scholar 

  433. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17(18):5858–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  434. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease—liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10(3):197–214.

    CAS  PubMed  Google Scholar 

  435. Cheuk DKL. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: prophylaxis and treatment controversies. World J Transplant. 2012;2(2):27–34.

    Article  PubMed  PubMed Central  Google Scholar 

  436. McDonald GB. Hepatobiliary complications of hematopoietic cell transplant, 40 years on. Hepatology. 2010;51(4):1450–60.

    Article  PubMed  PubMed Central  Google Scholar 

  437. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255–67.

    Article  CAS  PubMed  Google Scholar 

  438. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.

    Article  PubMed  Google Scholar 

  439. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83(7):1998–2004.

    CAS  PubMed  Google Scholar 

  440. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79(6):1178–91.

    CAS  PubMed  Google Scholar 

  441. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1):116–22.

    Article  CAS  PubMed  Google Scholar 

  442. Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant. 1996;17(1):75–80.

    CAS  PubMed  Google Scholar 

  443. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  444. Kaufman PA, Jones RB, Greenberg CS, Peters WP. Autologous bone marrow transplantation and factor xii, factor vii, and protein c deficiencies report of a new association and its possible relationship to endothelial cell injury. Cancer. 1990;66(3):515–21.

    Article  CAS  PubMed  Google Scholar 

  445. Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood. 1993;81(12):3458–62.

    CAS  PubMed  Google Scholar 

  446. Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D’Agay MF, et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63(5):509–19.

    Article  CAS  PubMed  Google Scholar 

  447. Iguchi A, Kobayashi R, Kaneda M, Kobayashi K. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation. Pediatr Blood Cancer. 2010;54(3):437–43.

    Article  PubMed  Google Scholar 

  448. Salat C, Holler E, Kolb H-J, Reinhardt B, Pihusch R, Wilmanns W, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997;89(6):2184–8.

    CAS  PubMed  Google Scholar 

  449. Park YD, Yasui M, Yoshimoto T, Chayama K, Shimono T, Okamura T, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19(9):915–20.

    Article  CAS  PubMed  Google Scholar 

  450. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75(4):1011–6.

    CAS  PubMed  Google Scholar 

  451. Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79(11):2834–40.

    CAS  PubMed  Google Scholar 

  452. Fogteloo AJ, Smid WM, Kok T, Van Der Meer J, Van Imhoff GW, Daenen S. Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin’s lymphoma. Leukemia. 1993;7(5):760–3.

    CAS  PubMed  Google Scholar 

  453. Bearman S, Shuhart M, Hinds M, McDonald G. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood. 1992;80(10):2458–62.

    CAS  PubMed  Google Scholar 

  454. Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4):444–57.

    Article  CAS  PubMed  Google Scholar 

  455. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111(4):1122–9.

    Article  CAS  PubMed  Google Scholar 

  456. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92(3):737–44.

    CAS  PubMed  Google Scholar 

  457. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  458. Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost. 2007;33(4):373–88.

    Article  PubMed  Google Scholar 

  459. Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16(7):1005–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  460. Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs. 2009;69(2):183–98.

    Article  CAS  PubMed  Google Scholar 

  461. Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001;113(1):58–64.

    Article  CAS  PubMed  Google Scholar 

  462. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994;14(4):495–504.

    CAS  PubMed  Google Scholar 

  463. Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant. 2002;30(11):709.

    Article  CAS  PubMed  Google Scholar 

  464. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44(2):294–304.

    Article  PubMed  Google Scholar 

  465. Dervenoulas J, Tsirigotis P, Bollas G, Pappa V, Xiros N, Economopoulos T, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol. 2000;79(2):66–72.

    Article  CAS  PubMed  Google Scholar 

  466. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am. 1996;10(2):485–97.

    Article  CAS  PubMed  Google Scholar 

  467. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011;118(6):1452–62.

    Article  CAS  PubMed  Google Scholar 

  468. Daly AS, Hasegawa WS, Lipton JH, Messner HA, Kiss TL. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci. 2002;27(1):3–12.

    Article  PubMed  Google Scholar 

  469. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  470. Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC, et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation. 2013;96(2):217–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  471. Kim SS, Patel M, Yum K, Keyzner A. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion. 2015;55(2):452–8.

    Article  CAS  PubMed  Google Scholar 

  472. Verburgh CA, Vermeij CG, Zijlmans JM, van Veen S, van Es LA. Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature. Nephrol Dial Transplant. 1996;11(7):1332–7.

    Article  CAS  PubMed  Google Scholar 

  473. Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant. 2010;45(4):699–704.

    Article  CAS  PubMed  Google Scholar 

  474. Magann EF, Martin JN Jr. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol. 1999;42(3):532–50.

    Article  CAS  PubMed  Google Scholar 

  475. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995;16(2):271–5.

    CAS  PubMed  Google Scholar 

  476. de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99(9):1953–9.

    Article  PubMed  CAS  Google Scholar 

  477. Au WY, Ma ES, Lee TL, Ha SY, Fung AT, Lie AK, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol. 2007;137(5):475–8.

    Article  CAS  PubMed  Google Scholar 

  478. Silva VA, Frei-Lahr D, Brown RA, Herzig GP. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apher. 1991;6(1):16–20.

    Article  CAS  PubMed  Google Scholar 

  479. Corti P, Uderzo C, Tagliabue A, Della Volpe A, Annaloro C, Tagliaferri E, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;29(6):542–3.

    Article  CAS  PubMed  Google Scholar 

  480. Uesawa M, Muroi K, Ozawa K. Plasmapheresis-refractory transplantation-associated thrombotic microangiopathy successfully treated with pravastatin and limaprost alfadex. Ther Apher Dial. 2013;17(4):462–3.

    Article  CAS  PubMed  Google Scholar 

  481. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571–5.

    Article  PubMed  Google Scholar 

  482. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA

    Joseph J. Shatzel M.D., Robyn Scherber M.D., M.P.H. & Thomas G. DeLoughery M.D. M.A.C.P., F.A.W.M.

  2. Medicine, Pathology, and Pediatrics, Department of Hematology MC L586, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239-3098, USA

    Thomas G. DeLoughery M.D. M.A.C.P., F.A.W.M.

Authors
  1. Joseph J. Shatzel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robyn Scherber M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas G. DeLoughery M.D. M.A.C.P., F.A.W.M.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas G. DeLoughery M.D. M.A.C.P., F.A.W.M. .

Editor information

Editors and Affiliations

  1. Cancer Research Foundation, Chappaqua, New York, USA

    Peter H. Wiernik

  2. Cancer Research Foundation, Chappaqua, New York, USA

    Janice P. Dutcher

  3. Department of Hematology, Mayo Clinic Department of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Shatzel, J.J., Scherber, R., DeLoughery, T.G. (2018). Bleeding and Thrombosis in Hematologic Neoplasia. In: Wiernik, P., Dutcher, J., Gertz, M. (eds) Neoplastic Diseases of the Blood. Springer, Cham. https://doi.org/10.1007/978-3-319-64263-5_59

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64263-5_59

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64262-8

  • Online ISBN: 978-3-319-64263-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation